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Abstract 
Prostate cancer screening with prostate specific antigen (PSA) is a controversial 
strategy – it reduces mortality but comes at  high cost in terms of over-diagnosis and 
overtreatment, particularly of low-grade prostate tumors.1 Due to considerable conflict 
within the literature and lack of prospective randomized studies comparing different 
screening protocols, recommendations differ across organizations regarding the 
frequency of screening, the age to start screening, interpretation of the screening 
results, and the diagnostic protocol to follow. However, many suggest that shared 
decision making must occur between the patient and the provider before any testing is 
done. In this paper, we propose an approach in which the shared decision-making is 
restricted to men found to have higher PSAs. Primary care physicians, including 
internists, order approximately 90% of all PSA screening tests, and shared decision-
making may present logistical challenges in this context. Evidence suggests that shared 
decision-making is difficult and many primary care physicians struggle with it. A 
straightforward and clinically feasible schema for screening decisions in primary care 
would be highly beneficial. A level PSA of <1.5 ng/ml constitutes a very low risk 
category for developing aggressive prostate cancer within 5 years or more. A suggested 
approach to PSA testing is to use 1.5 ng/ml as a clinical threshold, restricting further 
discussions or workup (i.e. biomarkers) to those above that threshold. Individuals with a 
PSA below this threshold can be offered rescreening in approximately 5 years, 
depending on life expectancy. This manuscript aims to provide guidance to physicians 
including primary care  regarding PSA screening. 
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Introduction: A Historical Perspective on Prostate Specific Antigen (PSA) 
Screening 
 
Prostate Cancer Epidemiology 
Prostate cancer is the most commonly diagnosed malignancy in males, but has one of 
the lowest percentage mortality compared to other cancers. An estimated 180,890 new 
cases of prostate cancer are expected to be diagnosed in 2016 and 26,120 men are 
expected to die from the disease. A significant dichotomy exists between the lifetime 
risk of being diagnosed versus dying from the disease. 17% of US males are diagnosed 
with prostate cancer within their lifetime, while only 3% die from the disease.2 The 
prevalence is highest in African American men, who also have a higher risk of mortality 
from prostate cancer.  Caucasian males have the next highest risk, while incidence is 
lower among those of Asian descent. 
 
Historical Perspective on PSA Screening 
Historically, there have been two ways to screen for prostate cancer: the digital rectal 
examination (DRE) and PSA blood test. In 1986, the Food and Drug Administration 
(FDA) approved PSA to be used in monitoring prostate cancer recurrence. In 1994, 
PSA was approved for screening, and was historically used in conjunction with the 
DRE.  
 
Screening with PSA has several limitations. Many men who do not have prostate cancer 
will screen positive and require a biopsy to rule out cancer, while a few men with 
aggressive prostate cancer have low PSA. Because many prostate cancers grow so 
slowly that they never threaten a patient’s life, there is a danger of overtreatment if 
these cancers are detected. This is a particularly important issue since treatment for 
prostate cancer is often associated with significant side effects. Our emphasis going 
forward should be finding the more aggressive cancers, while avoiding biopsy in those 
at low risk of cancer or those with indolent disease.  
 
Current Screening Recommendations and the Evidence 
 5 
 
Prostate Cancer Screening 
Screening is defined as the process of identifying apparently healthy people who may 
be at increased risk of a disease or condition. Current strategies for managing prostate 
cancer are mainly aimed at early detection. The potential risks incurred by screening, 
diagnosis, and the resulting over-treatment of prostate cancer have been well 
documented within the literature3. These include erectile dysfunction, incontinence and 
other complications from biopsies, surgery, radiation, or androgen deprivation therapy. 
The majority of the harms associated with over-treatment occur in men in whom 
prostate cancer would not have been detected in their lifetime had it not been for 
screening.4 However, rates of active surveillance are rising rapidly across the globe.5, 6 
Conversely, discontinuing screening altogether has been projected to increase the rates 
of metastatic disease7 and will preclude the opportunity for many men to receive life 
saving intervention. Given the substantial advantages and disadvantages associated 
with historical screening and management paradigms, many treating providers have 
been left without a clear roadmap.  
 
Screening Guidelines 
Screening recommendations from various organizations differ widely. The USPSTF and 
Canadian Task Force on Preventive Health Care have recommended against any 
screening for men of all ages, while most other organizations recommend some 
variation of shared decision-making. The American Urological Association does not 
recommend routine screening for men ages 50-55, but recommends shared decision-
making for men ages 55-69. The AUA further mentions that 2 year intervals can be 
considered to reduce harm.8 NCCN recommends a risk-based screening algorithm, 
including the patient’s age (screening should be considered at age 45; in the later 40s 
1.0 ng/ml is recommended by NCCN as a cutoff for screening within 2 years). Notably 
DRE is no longer first line in the 2015 NCCN guidelines.  
 
Data from separate European and American randomized screening trials showed 
divergent results. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
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Screening Trial did not show convincing evidence that PSA screening reduces prostate 
cancer mortality. However, a large majority of men in the control group also received 
PSA testing before and/or during the study so it was not comparison of screening vs. no 
screening but rather of organized versus opportunistic screening. The European 
Randomized Study of Screening for Prostate Cancer (ERSPC) found that screening 
reduces metastasis and prostate cancer death, but also leads to over-diagnosis. In both 
of these trials, biopsy was recommended based on a fixed PSA threshold.  An alternate 
approach to a fixed screening protocol is to use a risk-adapted approach.  For example, 
Thompson et al suggested that optimal PSA screening frequency for men with a PSA 
level of 0.1 to 1.0 ng/ml might be up to every 10 years. This approach has the potential 
to dramatically reduce the cost of screening, decreasing over detection of 
inconsequential tumors, while maintaining detection of tumors for which treatment has 
been proven to reduce prostate cancer mortality.9  
 
Screening in the Primary Care Setting 
Today, after nearly three decades since PSA was first used as a tool for the early 
detection of prostate cancer, substantial uncertainty surrounds its use. Shared decision-
making is ideal but may be difficult to implement in the primary care setting due to 
several factors, including: the limited time and availability that primary care clinicians 
have for in-depth discussions about the pros and cons of PSA testing, given the 
numerous other issues typically covered in a visit; the wide range of information and 
data that could be discussed during each visit; and the complex tradeoff between 
immediate harms and long-term benefits.10 Furthermore, it is important to note that 
shared decision making rarely occurs with many tests performed by PCPs – often times, 
it only occurs after an abnormality is detected. 
 
In some cases, spending considerable amounts of time in discussions about PSA may 
be seen as an inherent bias towards screening and could result in reducing the time 
spent on other preventive services, thereby resulting in an opportunity cost. Studies 
have found that only about half of primary care physicians are compliant with 
recommendations to discuss screening with eligible patients, with a large proportion 
 7 
adopting a default “screen all” or “screen none” approach.11 The value of a “detailed 
discussion” about PSA depends critically on the primary care providers’ knowledge. 
Less than one in five primary care providers report confidence in their knowledge about 
PSA, with a low correlation between confidence and actual knowledge.12, 13  A recent 
article in JAMA by Eggener et al acknowledged that a novel approach to prostate 
cancer screening is needed because of the workflow limitations in "discussing this 
complex decision" in the PCP office.10, 14 Assuming that some element of screening is 
embraced, there is a need to develop a simple/easy algorithm regarding the role of PSA 
in PC screening and to assess when further diagnostic tests are needed. 
 
A New Perspective on PSA Screening in the Primary Care Setting 
Rather than the fixed one-size-fits all approach used for screening in the past, there 
may be ways to use PSA more intelligently for more personalized decisions.  We need 
to avoid PSA tests in men who would have little to no gain by focusing on age and 
health. Several authors have targeted the relative risks of a baseline PSA and 
subsequent risk of an abnormal level of greater than 4 in 5 years.15, 16 In a 2011 article, 
Crawford et al found that a PSA of <1.5 ng/ml constitutes a very low risk category for 
developing prostate cancer (particularly high risk disease) within 4-5 years17. In a follow 
up piece, they suggested embracing the 1.5 ng/ml level and only having further 
discussions or workup with those above that threshold. An elevated PSA (>1.5ng/ml), 
becomes case finding (with a focus on identifying men who have a higher risk of having 
clinically significant disease). In such a case where there is increased suspicion of 
clinically significant disease, informed-decision-making should be employed, as several 
options are available as next steps. These options include following up with the patient 
in 6 months or 1 year, referral to a urologist, or using new techniques, such as MRI or 
biomarkers to determine whether the patient is at risk of harboring clinically significant 
disease. For those below the level, recommendations were made to screen again in 5 
years. Potential benefits of this approach include reducing the cost of screening, 
decreasing over detection of inconsequential tumors, and maintaining detection of 
tumors for which treatment has been proven to reduce prostate cancer mortality.9  
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Some suggest that a change in screening that leads to the biggest health gain is to stop 
screening older men. This applies to the majority of men over 70 and those over 60 with 
low PSA (e.g. < 1.5) when they get to the age of 60.18, 19  Indeed, Lilja et al found that a 
single PSA measured in white men between 44- 50 years was highly correlated with 
any cancer, palpable disease and advanced cancer. At a PSA threshold of 1.5 ng/ml 
theses values were approximately 20%, <15%, and 5% respectively 20-25 years after 
blood drawn when they were 44-50 years of age. Similarly Vickers et al showed that for 
white men with a PSA in the highest 10th grouping (i.e., 1.6ng/ml or greater) at age 45-
49 contributed to nearly half of all prostate cancer deaths over the next 25-30 years. 
They further postulated that low risk men based on baseline PSA might only need three 
PSA measurements in their lifetime (i.e., 40s, 50 and age 60). Little is known, however, 
whether these long-term data apply to men of other racial and ethnic groups.20, 21 
Crawford et al showed however that at least over a 4 year period both Caucasian and 
African American men were at low risk for any cancer diagnosis (i.e., 0.51,0.54% 
respectively) when their baseline serum PSA level was less than 1.5 ng/ml.17 Of note, 
among both African American and Caucasian men a substantial majority of PSA values 
were less than 1.5ng/ml (79 and 80% respectively).17 
 
Next Generation of Clinical Decision Making Tools 
Under the proposed paradigm (Figure 1; Supplemental Figure 1), PSA can be 
performed as part of a regular blood panel and only men with a PSA ≥ 1.5 ng/ml require 
shared decision-making about further testing and diagnostic evaluation.  This will greatly 
limit the number of men requiring such a discussion and can be performed either by the 
PCP or by referral to a urologist.  Men with elevated PSA levels should be evaluated for 
benign causes. Repeat testing of PSA and secondary tests such as SelectMDx, 
4KScore, PHI, mpMRI can be used to refine the specificity of screening to detect high-
risk disease. Sampling error is an inherent and well-documented issue with false-
negative rates of prostate biopsy procedures reported as high as 25-35%.22, 23 This 
results in repeat biopsies, which are associated with additional risks of infection and 
hospitalization, and with significant costs.  
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Conclusion 
Although many organizations now recommend shared decision-making when it comes 
to PSA testing, this can present many logistical challenges in daily clinical practice and 
is not always realistic. Furthermore, we acknowledge that several groups recommend 
for informed decision-making to take place before the PSA test is ordered. However, our 
aim is to draw a parallel to what happens in the real world for primary practice 
physicians – i.e., informed decision-making typically comes after the test results (be it 
blood sugar, blood pressure, cholesterol, or in this case PSA) are known. We believe 
that a simple message using a PSA cutoff of 1.5 ng/ml is reflective of what family 
practice physicians often experience in their practices with conditions such as mild 
hypertension and pre-diabetes. In this paper, we have presented an alternative 
approach in which screening is performed for men with at least a 10-year life 
expectancy. If the PSA is less than 1.5 ng/ml, consider a 5-year re-screening interval. If 
the PSA is 1.5 ng/ml or greater, or the PCP identifies an abnormality on DRE, refer to a 
specialist or consider a biomarker to assess risk more precisely. This algorithm is 
similar to that utilized for an elevated blood sugar, where an abnormal result triggers 
another test such as an A1C hemoglobin. In our algorithm, we recommend that a biopsy 
should not be performed unless the risk of an aggressive tumor is significant, and 
following a thorough discussion of benefits and risks with the patient. These discussions 
should emphasize that the purpose of screening is the early identification of potentially 
lethal disease, and that in most cases low-risk tumors, if identified, do not require 
immediate treatment. A potential benefit of this approach is that it could greatly reduce 
the number of men requiring shared decision-making and further testing to those at 
greater risk of significant prostate cancer.  
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Figure 1: Role of PSA Testing in the Prostate Cancer Diagnostic Pathway within a 
Primary Care Setting  
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Supplemental Figure 1: Approach to Shared Care in Prostate Cancer Diagnosis  
 
 
 
 
 
 
 
Family	Prac oner	 Urologist	
Rou ne	
Lab/PSA	
PSA	<1.5	
Repeat	PSA			
5	years	
PSA	>1.5	
PHI,	
PCA3,4K	
Low	Risk	
High	Risk	
TRUS	Bx	
Gleason	Score	≥4+3	
Gleason	Score	6			
or	3+4	
+ 
Consider	Tx	
- 
ConfirmMDx	
+ 
MP	MRI	
- 
Genomic	Markers	
Consider	Tx	
Ac ve	Surveillance	
High Risk 
Low Risk 
Consider	referral		to	
Urologist	
 
© 2015 E.D. Crawford 
